Cargando…

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543922/ https://www.ncbi.nlm.nih.gov/pubmed/37791042 http://dx.doi.org/10.2147/JAA.S441410

Ejemplares similares

Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR
por: Laidlaw, Tanya M, et al.
Publicado: (2023)

Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study
por: Menzies-Gow, Andrew, et al.
Publicado: (2023)

Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis
por: Zoumot, Zaid, et al.
Publicado: (2022)

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study
por: Emson, Claire, et al.
Publicado: (2021)

The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials
por: Roy, Pooja, et al.
Publicado: (2022)

Safety and efficacy of tezepelumab vs. placebo in adult patients with severe uncontrolled asthma: a systematic review and meta-analysis
por: Shaban Abdelgalil, Mahmoud, et al.
Publicado: (2022)

Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma
por: Plaza, Vicente, et al.
Publicado: (2023)

Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma
por: Alpizar, Sady, et al.
Publicado: (2021)

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

Effect of benralizumab in a patient with uncontrolled severe eosinophilic asthma and comorbid chronic rhinosinusitis with nasal polyps refractory to mepolizumab treatment
por: Mansur, Adel H.
Publicado: (2021)

The efficacy and safety of tezepelumab in the treatment of uncontrolled asthma: A systematic review and meta-analysis of randomized controlled trials
por: Lin, Fei, et al.
Publicado: (2023)

Dupilumab and tezepelumab in severe refractory asthma: new opportunities
por: Ragnoli, Beatrice, et al.
Publicado: (2022)

Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
por: Menzies-Gow, Andrew, et al.
Publicado: (2020)

Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma
por: Langley, Paul C
Publicado: (2022)

Transcriptional Changes in Chronic Rhinosinusitis with Asthma Favor a Type 2 Molecular Endotype Independent of Polyp Status [Corrigendum]
Publicado: (2021)

Real-World Cost of Nasal Polyps Surgery and Risk of Major Complications in the United States: A Descriptive Retrospective Database Analysis [Corrigendum]
Publicado: (2023)

Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab
por: van Dijk, Yoni E., et al.
Publicado: (2023)

Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab
por: Cheng, Shih-Lung
Publicado: (2021)

Tezepelumab as an Emerging Therapeutic Option for the Treatment of Severe Asthma: Evidence to Date
por: Dorey-Stein, Zachariah L, et al.
Publicado: (2021)

Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

Baseline type 2 biomarker levels and response to tezepelumab in severe asthma
por: Corren, Jonathan, et al.
Publicado: (2022)

The potential promise and challenge for tezepelumab as a biologic therapy for severe asthma
por: Williams, Dennis M
Publicado: (2022)

Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
por: Corren, Jonathan, et al.
Publicado: (2021)

Biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: A bicentric experience
por: Bellocchi, Gianluca, et al.
Publicado: (2023)

Identification of a circRNA/miRNA/mRNA ceRNA Network as a Cell Cycle-Related Regulator for Chronic Sinusitis with Nasal Polyps [Corrigendum]
Publicado: (2022)

Biological Therapy of Severe Asthma and Nasal Polyps
por: Bakakos, Agamemnon, et al.
Publicado: (2022)

Bronchiectasis in COPD patients: more than a comorbidity? [Corrigendum]
Publicado: (2019)

Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction [Corrigendum]
Publicado: (2021)

Corrigendum to “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium”
por: Hamelmann, Eckard
Publicado: (2019)

Corrigendum to “Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp”
por: Mahamid, Mahmud, et al.
Publicado: (2017)

Navigating Personal and Professional Development Through Social Media in Ophthalmology [Corrigendum]
Publicado: (2023)

Nasal high-flow in acute hypercapnic exacerbation of COPD [Corrigendum]
Publicado: (2019)

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma
por: Emson, Claire, et al.
Publicado: (2020)

Corrigendum to: Navigating the way to onchocerciasis elimination: the feasibility and affordability of Onchocerciasis Elimination Mapping
Publicado: (2022)

Disrupted Expression of Circadian Clock Genes in Patients with Bronchial Asthma [Corrigendum]
Publicado: (2021)

Clinical Characteristics of Patients and Factors Associated with Switching Biologics in Asthma [Corrigendum]
Publicado: (2022)

Adaptation of the Charlson Comorbidity Index for Register-Based Research in Sweden [Corrigendum]
Publicado: (2023)

Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference?
por: Al-Ahmad, Mona, et al.
Publicado: (2023)

Profile of Anti-IL-5 mAb Mepolizumab in the Treatment of Severe Refractory Asthma and Hypereosinophilic Diseases [Corrigendum]
Publicado: (2021)

Burden of comorbidities among Japanese patients with atrial fibrillation: a case study of dyspepsia [Corrigendum]
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gpn823pjnaafmg1c3ud49an86s